Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Memorial Sloan Kettering Cancer Center, New York

Institut Paoli Calmettes (Marseille), Marseille

Roswell Park Cancer Institute, Buffalo

Instituto Europeo di Oncologia, Milan

University of Maryland Medical Center, Baltimore

CHU de Besancon, Hopital Jean Minjoz, Besançon

Novant Health Cancer Institute Hematology - Forsyth, Winston-Salem

Duke Cancer Institute, Durham

Novant Health Cancer Institute Hematology, Charlotte

CHU Bordeaux Hôpital Haut-Lévêque, Pessac

Moffitt Cancer Center, Tampa

IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna

Hospital Universitari I Politècnic La Fe, Valencia

Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola

University Hospital of Cologne, Cologne

Baylor Scott & White University Medical Center, Dallas

Banner Health MD Anderson Cancer Center, Gilbert

UCLA, Los Angeles

City of Hope Medical Center, Duarte

Stanford, Stanford

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle

Dana-Farber Cancer Institute, Boston

MD Anderson Cancer Center, Houston

Recherche Clinique-Hématologie, Amiens

Hôpital St Antoine, Paris

University Hospital of Leipzig, Leipzig

Azienda ospedaliera Santa Maria della Misericordia, Perugia

Churchill Hospital - Oxford, Oxford